This study is testing a new treatment combination called RAVEN, which includes revumenib, azacitidine, and venetoclax, in patients who are newly diagnosed with…

Leukemia Acute Myeloid

~Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT07605949

Phase 1

A Phase 1 Study of BAL0891 as Monotherapy and in Combination With Chemotherapy or Tislelizumab in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, a…

Advanced Solid TumorTNBC - Triple-Negative Breast CancerGastric Cancer+1 more

~Estimated

~$10 – $8,750

SillaJen, Inc.NCT05768932